Jesup & Lamont Downgrades Draxis Health (DRAX) to Neutral
More News related to DRAX
- Jesup & Lamont Downgrades Draxis Health (DRAX) to Neutral
- Unusual 11 Mid-Day Movers 4/4: DRAX, COCO, MEE, JASO Higher; OFIX, DMAN, TGIC, BCSI Lower
- DRAXIS Health (DRAX) Resumes Trading -Bloomberg
- DRAXIS (DRAX) To Be Acquired By Jubiliant for $255M
- DRAXIS Health (DRAX) in Discussions Regarding Potential Transaction That Could Lead to Sale of the Company
More News related to Downgrades
- Top 10 News Items 11/23-11/27: Dubai Debt Fallout; Gold; GDP Revised Lower; Diedrich Coffee Bidding War
- Trading Radar for 11/30: Inergy Holdings (NRGP), Golar (GLNG), Omnivision (OVTI), Knightsbridge (VLCCF) Report
- Notable Mergers and Acquisitions of the Day for 11/27: F, S/IPCS, STAR/CSCO, HRAY
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Notable ETF Movers *Special Dubai World Edition* 11/27: UUP Higher; GAF, EEM, FXI, XLF Lower
Jesup & Lamont downgrades Draxis Health (Nasdaq: DRAX) to Neutral, citing a favorable buyout agreement by Jubilant.
The firm calls Jubilant's $6 offer for Draxis "fair", as it represents a 20%+ premium from its closing price the day before the acquisition was announced. Jesup & Lamont believes the chances of another bidder coming in to make an offer are slim as the deal includes a $10.5 million break-up fee.
Draxis Health, Inc., through its wholly owned subsidiary, DRAXIS Specialty Pharmaceuticals, Inc., provides products in the areas of sterile, nonsterile, and radiopharmaceuticals. [BCS]
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
